Asthma vs COPD: How to Tell Them Apart
Asthma and COPD are the two classic obstructive lung diseases—both limit expiratory airflow and both produce wheezing and dyspnea. The core axis that separates them is reversibility: asthma is (at least partially) reversible airway obstruction driven by bronchial hyperresponsiveness and Th2 inflammation, whereas COPD is largely irreversible obstruction from smoking-related emphysema and chronic bronchitis. Confirm the distinction with objective spirometry rather than assuming "wheezing = asthma."
How to tell them apart
| Feature | Asthma | COPD |
|---|---|---|
| Reversibility of obstruction | Reversible, at least partially; usually shows a significant bronchodilator response | Largely irreversible/fixed obstruction; usually minimal bronchodilator response |
| Temporal pattern of onset | Exacerbations come on acutely over minutes to hours | Dyspnea develops chronically over months to years; exacerbations are subacute over days |
| Underlying pathophysiology | Bronchial hyperresponsiveness with Th2 (IL-4, IL-5, IL-13)–driven inflammation, IgE production, and eosinophil/mast cell activation; no parenchymal destruction | Emphysema (parenchymal destruction) plus chronic bronchitis (airway disease) |
| Typical cause and risk factors | Atopy and allergic triggers; often childhood symptoms | Usually cigarette smoking; occasionally alpha-1 antitrypsin deficiency (young, non-smoking, lower-lobe panacinar emphysema) |
| Diurnal symptom pattern | Symptoms characteristically worse at night | Symptoms worse in the morning from overnight mucus accumulation |
| Cornerstone of therapy | Inhaled corticosteroids (ICS) are the cornerstone; anti-inflammatory reliever (low-dose ICS-formoterol) is preferred over SABA alone | Long-acting bronchodilators (LAMA and/or LABA) are first-line; ICS is added only for frequent exacerbators, eosinophilia, or asthma-COPD overlap |
| Gas exchange in advanced/exacerbated disease | Acute attacks can progress to rising PaCO2 and respiratory fatigue as a marker of deterioration | Chronic CO2 retention with V/Q mismatch (elevated A-a gradient) and compensatory elevated bicarbonate indicating chronicity |
| Role of ICS safety | ICS is standard and disease-modifying, reducing exacerbations and airway remodeling | ICS must be used judiciously because it increases pneumonia risk |
The reasoning
Anchor on reversibility. Start with spirometry: both diseases show an obstructive pattern, but the bronchodilator response arbitrates—robust reversibility points to asthma, while a fixed obstruction points to COPD. Layer in the history: childhood symptoms and atopy suggest asthma, whereas a heavy smoking history in an older patient with chronic, slowly progressive dyspnea suggests COPD. Consider alpha-1 antitrypsin deficiency when emphysema appears in a young non-smoker with lower-lobe disease. Recognize that features can coexist: a patient with persistent airflow limitation who also shows significant bronchodilator response or marked variability, plus both an asthma history and COPD risk factors, has asthma-COPD overlap—these patients need ICS. Always confirm the diagnosis with objective testing rather than anchoring on wheeze alone.
Key tests
- Spirometry with bronchodilator challenge: a significant response (≥12% AND ≥200 mL improvement in FEV1 or FVC) favors asthma's reversible obstruction; minimal response favors COPD's fixed obstruction.
- Arterial blood gas: COPD may show chronic hypercapnia with metabolic (bicarbonate) compensation and an elevated A-a gradient from V/Q mismatch; useful to detect acute-on-chronic respiratory failure in exacerbations.
- Blood eosinophil count: eosinophilia (≥300 cells/µL) reflects Th2 inflammation—central to asthma and, in COPD, identifies patients more likely to benefit from added ICS.
- Alpha-1 antitrypsin testing: pursue in young (<45), non-smoking patients with lower-lobe emphysema to identify a non-smoking cause of COPD.
- Chest CT: demonstrates parenchymal destruction (emphysema) in COPD, which is absent in uncomplicated asthma.
What they share
- Airflow limitation on spirometry (obstructive pattern) with prolonged expiration
- Wheezing and dyspnea, often with cough
- Airway narrowing that is worse during expiration (bronchospasm, mucus plugging, airway wall thickening)
- Tripod positioning and use of accessory muscles during severe exacerbations
- A "silent chest" with diminished breath sounds when obstruction is severe enough that too little air moves to generate sound
- Short-acting bronchodilators (SABA) used for rescue of acute symptoms
Pitfalls
- Assuming "all that wheezes is asthma"—heart failure, foreign body aspiration, anaphylaxis, and PE can all wheeze; confirm obstruction and reversibility objectively.
- Interpreting quieter wheezing in a deteriorating asthmatic as improvement—a "silent chest" with drowsiness signals such poor air movement and hypercapnia that respiratory arrest is imminent.
- Overusing ICS in COPD—unlike asthma, ICS is not standard for all COPD and raises pneumonia risk; reserve it for exacerbators, those with eosinophilia (≥300), or asthma-COPD overlap.
- Forgetting asthma-COPD overlap—patients with features of both have more frequent exacerbations, worse quality of life, and require ICS.
- Missing alpha-1 antitrypsin deficiency by attributing all emphysema to smoking; young non-smokers with lower-lobe emphysema need testing.
- Relying on SABA monotherapy in asthma—this fails to treat the underlying inflammation, increases exacerbation risk, and frequent use is itself a marker of poor control.
Practice this the way the exam tests it — on branching cases where your decisions shape the patient.